BioMarin Pharmaceutical, Inc (BMRN) Covered Calls

BioMarin Pharmaceutical, Inc covered calls Biomarin Pharmaceutical, Inc. develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. Its Approved products include Naglazyme, Kuvan tablets, Aldurazyme and Firdapse.

You can sell covered calls on BioMarin Pharmaceutical, Inc to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for BMRN (prices last updated Fri 4:16 PM ET):

BioMarin Pharmaceutical, Inc (BMRN) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
92.70 -0.99 91.51 99.00 690K - 0.0B
Covered Calls For BioMarin Pharmaceutical, Inc (BMRN)
Expiration Strike Call Bid Net Debit Return
If Flat
Return If Flat
Dec 21 95 2.15 96.85 -1.9% -46.2%
Jan 18 95 4.00 95.00 0.0% 0.0%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

BioMarin Pharmaceutical, Inc. develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. The company operates its business through one segment, the biopharmaceutical development and commercialization segment. Its company's product portfolio is comprised of five approved products and multiple investigational product candidates which include Naglazyme, Kuvan, Aldurazyme, Firdapse and VIMIZIM. Naglazyme is a recombinant form of N-acetylgalactosamine 4-sulfatase indicated for patients with ucopolysaccharidosis VI. MPS VI is a debilitating life-threatening genetic disease for which no other drug treatment currently exists and is caused by the deficiency of arylsulfatase B, an enzyme normally required for the breakdown of certain complex carbohydrates known as glycosaminoglycans, or GAGs. Kuvan is a proprietary synthetic oral form of 6R-BH4, a naturally occurring enzyme co-factor for phenylalanine hydroxylase, indicated for patients with PKU, which is an inherited metabolic disease that affects patients under the age of 40 in the developed world. Aldurazyme has been approved for marketing in the U.S., EU and other countries for patients with mucopolysaccharidosis. Firdapse is a form of 3, 4-diaminopyridine for the treatment of Lambert Myasthenic Syndrome. And VIMIZIM is an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. The company was founded on March 21, 1997 and is headquartered in Novato, CA.